INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Atara Biotherapeutics, Inc. following a significant stock price drop after the FDA's Complete Response Letter regarding its drug EBVALLO™ [1][3]. Group 1: Company Overview - Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing therapies for patients with serious diseases [1]. - The company’s stock experienced a dramatic decline of 56.99%, falling $7.79 to close at $5.88 per share on January 12, 2026, after the FDA's announcement [3]. Group 2: FDA Response - On January 12, 2026, Atara announced that the FDA issued a Complete Response Letter (CRL) for its EBVALLO™ Biologics License Application (BLA) for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease [3]. - The CRL indicated that the FDA could not approve the BLA in its current form, citing inadequacies in the evidence of effectiveness from the single arm ALLELE trial [3].